Table 1.
Clinical features of 30 participants.
| Healthy control (n=10) | AChR-positive MG (n=10) | Seronegative MG (n=10) | |
|---|---|---|---|
| Age, years | 41.3 ± 10.7 | 45.2 ± 11.3 | 43.1 ± 9.8 |
| Female sex | 10 (100%) | 10 (100%) | 10 (100%) |
| Onset age, years | 33.9 | 31.8 | |
| Disease duration, years | 11.3 | 11.2 | |
| MGFA classification | |||
| Mild generalized | 8 (80%) | 0 (0%) | |
| Moderate generalized | 2 (20%) | 8 (80%) | |
| Severe generalized | 0 | 2 (20%) | |
| Bulbar symptoms | 4 (40%) | 10 (100%) | |
| Myasthenic crisis | 0 (0%) | 0 (0%) | |
| AChR Ab positive | 10 (100%) | 0 (0%) | |
| Treatment | |||
| Thymectomy | 4 (40%) | 1 (10%) | |
| Prednisolone | 0 (0%) | 10 (100%) | |
| Calcineurin inhibitors | 0 (0%) | 10 (100%) | |
| IVIg | 0 (0%) | 10 (100%) | |
| Plasmapheresis | 0 (0%) | 4 (40%) | |
| Postinterventional status | |||
| Minimal manifestations | 5 (50%) | 0 (0%) | |
| Improved | 4 (40%) | 3 (30%) | |
| Unchanged | 1 (10%) | 7 (70%) | |
| Clinical scales* | |||
| MGC | 4.2 ± 3.1 | 21.1 ± 3.8/16.8 ± 2.9 | |
| MG-ADL | 3.2 ± 2.0 | 14.0 ± 1.3/10.7 ± 1.3 | |
| 15-item MG-QOL | 5.8 ± 4.6 | 20.1 ± 5.0/15.4 ± 3.8 | |
*Clinical scales were evaluated pre- and post-intravenous immunoglobulin (IVIg) treatment in seronegative myasthenia gravis (MG) patients (indicated as pre- and post- IVIg).
AChR, acetylcholine receptor; MGC, MG composite scale; MG-ADL, MG-Activities of Daily Living.